

Takuya Osada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7862857/publications.pdf>

Version: 2024-02-01

31
papers

1,346
citations

430874

18
h-index

477307

29
g-index

31
all docs

31
docs citations

31
times ranked

2353
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1115-1124. | 4.2 | 271 |
| 2 | Antihelminth Compound Niclosamide Downregulates Wnt Signaling and Elicits Antitumor Responses in Tumors with Activating APC Mutations. <i>Cancer Research</i> , 2011, 71, 4172-4182. | 0.9 | 239 |
| 3 | Dendritic Cell-Based Immunotherapy. <i>International Reviews of Immunology</i> , 2006, 25, 377-413. | 3.3 | 93 |
| 4 | CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 677-688. | 4.2 | 75 |
| 5 | Preclinical Evaluation of ¹⁸ F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET. <i>Journal of Nuclear Medicine</i> , 2016, 57, 967-973. | 5.0 | 68 |
| 6 | NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1122-1131. | 4.2 | 63 |
| 7 | Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. <i>Clinical Cancer Research</i> , 2019, 25, 2725-2736. | 7.0 | 50 |
| 8 | Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy. <i>Biochemical Journal</i> , 2019, 476, 535-546. | 3.7 | 44 |
| 9 | Optical and Radioiodinated Tethered Hsp90 Inhibitors Reveal Selective Internalization of Ectopic Hsp90 in Malignant Breast Tumor Cells. <i>Chemistry and Biology</i> , 2013, 20, 1187-1197. | 6.0 | 43 |
| 10 | A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy <i>in Vivo</i> . <i>ACS Chemical Biology</i> , 2017, 12, 1047-1055. | 3.4 | 40 |
| 11 | Effect of the vaccine Ad5 [E1-, E2b-]-CEA(6D) on CEA-directed CMI responses in patients with advanced CEA-expressing malignancies in a phase I/II clinical trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2585-2585. | 1.6 | 38 |
| 12 | Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1500-1509. | 4.1 | 36 |
| 13 | Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs. <i>International Immunology</i> , 2005, 17, 1143-1155. | 4.0 | 35 |
| 14 | Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 2481-2493. | 7.0 | 33 |
| 15 | Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity. , 2022, 10, e003717. | | 27 |
| 16 | X-Ray Psoralen Activated Cancer Therapy (X-PACT). <i>PLoS ONE</i> , 2016, 11, e0162078. | 2.5 | 23 |
| 17 | Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1941-1951. | 4.2 | 22 |
| 18 | N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: Influence of isomeric substitution on radiolabeling and target cell residualization. <i>Nuclear Medicine and Biology</i> , 2014, 41, 802-812. | 0.6 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors. <i>Communications Biology</i> , 2020, 3, 226. | 4.4 | 18 |
| 20 | Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition. <i>Onc Immunology</i> , 2017, 6, e1315495. | 4.6 | 17 |
| 21 | <i>In Vivo</i> Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior. <i>Clinical Cancer Research</i> , 2017, 23, 7531-7542. | 7.0 | 15 |
| 22 | Novel Recombinant Alphaviral and Adenoviral Vectors for Cancer Immunotherapy. <i>Seminars in Oncology</i> , 2012, 39, 305-310. | 2.2 | 14 |
| 23 | Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. <i>Breast Cancer Research</i> , 2018, 20, 90. | 5.0 | 14 |
| 24 | Induction of Wilms' Tumor Protein (WT1)–Specific Antitumor Immunity Using a Truncated WT1-Expressing Adenovirus Vaccine. <i>Clinical Cancer Research</i> , 2009, 15, 2789-2796. | 7.0 | 13 |
| 25 | Right Time and Place for IL12: Targeted Delivery Stimulates Immune Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 9-11. | 7.0 | 10 |
| 26 | Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 391-397. | 0.5 | 9 |
| 27 | Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growth. <i>Immunotherapy</i> , 2019, 11, 953-966. | 2.0 | 8 |
| 28 | Effect of alphavirus vaccine encoding HER2 during concurrent anti-HER2 therapies on induction of oligoclonal T cell and antibody responses against HER2. <i>Journal of Clinical Oncology</i> , 2015, 33, 3081-3081. | 1.6 | 4 |
| 29 | Effect of the loss of the type III TGF β receptor during tumor progression on tumor microenvironment: Preclinical development of TGF β inhibition and TGF β -related biomarkers to enhance immunotherapy efficacy. <i>Journal of Clinical Oncology</i> , 2012, 30, 10563-10563. | 1.6 | 3 |
| 30 | HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 217-226. | 4.1 | 2 |
| 31 | Functional genomic screens and identification of signaling pathways in oxaliplatin-resistance in colorectal cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3611-3611. | 1.6 | 0 |